- Home
- HCWB vs KRKR Comparison
HCWB vs KRKR Comparison
Compare HCWB & KRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- KRKR
- Stock Information
- Founded
- HCWB 2018
- KRKR 2010
- Country
- HCWB United States
- KRKR China
- Employees
- HCWB N/A
- KRKR N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- KRKR Business Services
- Sector
- HCWB Health Care
- KRKR Consumer Discretionary
- Exchange
- HCWB Nasdaq
- KRKR Nasdaq
- Market Cap
- HCWB 10.8M
- KRKR 9.9M
- IPO Year
- HCWB 2021
- KRKR 2019
- Fundamental
- Price
- HCWB $4.62
- KRKR $5.12
- Analyst Decision
- HCWB Strong Buy
- KRKR
- Analyst Count
- HCWB 1
- KRKR 0
- Target Price
- HCWB $35.00
- KRKR N/A
- AVG Volume (30 Days)
- HCWB 113.8K
- KRKR 20.4K
- Earning Date
- HCWB 08-18-2025
- KRKR 09-03-2025
- Dividend Yield
- HCWB N/A
- KRKR N/A
- EPS Growth
- HCWB N/A
- KRKR N/A
- EPS
- HCWB N/A
- KRKR N/A
- Revenue
- HCWB $1,445,145.00
- KRKR $31,657,328.00
- Revenue This Year
- HCWB $178.36
- KRKR $182.55
- Revenue Next Year
- HCWB N/A
- KRKR N/A
- P/E Ratio
- HCWB N/A
- KRKR N/A
- Revenue Growth
- HCWB N/A
- KRKR N/A
- 52 Week Low
- HCWB $3.55
- KRKR $2.76
- 52 Week High
- HCWB $100.80
- KRKR $12.99
- Technical
- Relative Strength Index (RSI)
- HCWB 52.11
- KRKR 47.62
- Support Level
- HCWB $4.02
- KRKR $4.44
- Resistance Level
- HCWB $4.61
- KRKR $5.56
- Average True Range (ATR)
- HCWB 0.30
- KRKR 0.56
- MACD
- HCWB 0.09
- KRKR 0.02
- Stochastic Oscillator
- HCWB 100.00
- KRKR 51.38
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About KRKR 36Kr Holdings Inc.
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.